Incidence of adverse reactions in HIV patients treated with protease inhibitors: A cohort study

Paolo Bonfanti, Laura Valsecchi, Fabio Parazzini, Silvia Carradori, Luigi Pusterla, Paolo Fortuna, Lia Timillero, Federica Alessi, Giancarlo Ghiselli, Andrea Gabbuti, Elisabetta Di Cintio, Canio Martinelli, Ivano Faggion, Simona Landonio, Tiziana Quirino

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Objective: To assess the probability that protease inhibitor (PI) therapy might be discontinued because of adverse events (AE) and to evaluate the incidence rate of adverse reactions during PI treatment. Design: A prospective cohort, multicenter study on HIV-positive patients starting treatment with at least one PI. Setting: Ten departments of infectious diseases in Northern Italy. Patients: A total of 1207 patients who started PI therapy in September 1997 and were consecutively observed up to April 1999. Main Outcome Measures: Adverse reactions following initiation of PI therapy, and time to therapy discontinuation due to AE. Results: During the study period, 35.9% patients presented adverse reactions of any grade, whereas 9.7% presented at least one serious AE. After 12 months of treatment, the percentage of patients who had interrupted treatment was 36% of ritonavir- treated patients, 14.2% of those treated with indinavir, 13.6% of ritonavir- saquinavir hard gel capsules (HGC)-treated patients, and 8.5% and 2.1%, respectively, for those treated with nelfinavir and saquinavir HGC. Women and patients with hepatitis experienced a significantly greater number of adverse events compared with other categories. Gastrointestinal events were more frequently observed in patients treated with either ritonavir alone or in combination with saquinavir HGC, as well as in patients receiving nelfinavir, although in this group serious events were rare. Here again, neurologic, metabolic, and hepatic toxicity occurred more frequently in ritonavir and ritonavir-saquinavir HGC treated patients. Allergic reactions were more often observed in patients receiving nelfinavir. Indinavir-treated patients presented the highest incidence of renal toxicity. Conclusion: Ritonavir is the drug associated with the largest number of reactions, which appear during the first few months of treatment. Saquinavir HGC and nelfinavir are the best tolerated drugs in a clinical setting.

Original languageEnglish
Pages (from-to)236-245
Number of pages10
JournalJournal of Acquired Immune Deficiency Syndromes
Volume23
Issue number3
Publication statusPublished - Mar 1 2000

Fingerprint

Protease Inhibitors
Cohort Studies
HIV
Ritonavir
Incidence
Saquinavir
Nelfinavir
Capsules
Gels
Indinavir
Therapeutics
Pharmaceutical Preparations
Nervous System
Italy
Hepatitis
Multicenter Studies
Communicable Diseases
Hypersensitivity
Outcome Assessment (Health Care)
Kidney

Keywords

  • Adverse reactions
  • Antiretroviral therapy
  • Protease inhibitors
  • Surveillance

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Bonfanti, P., Valsecchi, L., Parazzini, F., Carradori, S., Pusterla, L., Fortuna, P., ... Quirino, T. (2000). Incidence of adverse reactions in HIV patients treated with protease inhibitors: A cohort study. Journal of Acquired Immune Deficiency Syndromes, 23(3), 236-245.

Incidence of adverse reactions in HIV patients treated with protease inhibitors : A cohort study. / Bonfanti, Paolo; Valsecchi, Laura; Parazzini, Fabio; Carradori, Silvia; Pusterla, Luigi; Fortuna, Paolo; Timillero, Lia; Alessi, Federica; Ghiselli, Giancarlo; Gabbuti, Andrea; Di Cintio, Elisabetta; Martinelli, Canio; Faggion, Ivano; Landonio, Simona; Quirino, Tiziana.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 23, No. 3, 01.03.2000, p. 236-245.

Research output: Contribution to journalArticle

Bonfanti, P, Valsecchi, L, Parazzini, F, Carradori, S, Pusterla, L, Fortuna, P, Timillero, L, Alessi, F, Ghiselli, G, Gabbuti, A, Di Cintio, E, Martinelli, C, Faggion, I, Landonio, S & Quirino, T 2000, 'Incidence of adverse reactions in HIV patients treated with protease inhibitors: A cohort study', Journal of Acquired Immune Deficiency Syndromes, vol. 23, no. 3, pp. 236-245.
Bonfanti, Paolo ; Valsecchi, Laura ; Parazzini, Fabio ; Carradori, Silvia ; Pusterla, Luigi ; Fortuna, Paolo ; Timillero, Lia ; Alessi, Federica ; Ghiselli, Giancarlo ; Gabbuti, Andrea ; Di Cintio, Elisabetta ; Martinelli, Canio ; Faggion, Ivano ; Landonio, Simona ; Quirino, Tiziana. / Incidence of adverse reactions in HIV patients treated with protease inhibitors : A cohort study. In: Journal of Acquired Immune Deficiency Syndromes. 2000 ; Vol. 23, No. 3. pp. 236-245.
@article{90b908ef69f64e789b0c251c27d0faf0,
title = "Incidence of adverse reactions in HIV patients treated with protease inhibitors: A cohort study",
abstract = "Objective: To assess the probability that protease inhibitor (PI) therapy might be discontinued because of adverse events (AE) and to evaluate the incidence rate of adverse reactions during PI treatment. Design: A prospective cohort, multicenter study on HIV-positive patients starting treatment with at least one PI. Setting: Ten departments of infectious diseases in Northern Italy. Patients: A total of 1207 patients who started PI therapy in September 1997 and were consecutively observed up to April 1999. Main Outcome Measures: Adverse reactions following initiation of PI therapy, and time to therapy discontinuation due to AE. Results: During the study period, 35.9{\%} patients presented adverse reactions of any grade, whereas 9.7{\%} presented at least one serious AE. After 12 months of treatment, the percentage of patients who had interrupted treatment was 36{\%} of ritonavir- treated patients, 14.2{\%} of those treated with indinavir, 13.6{\%} of ritonavir- saquinavir hard gel capsules (HGC)-treated patients, and 8.5{\%} and 2.1{\%}, respectively, for those treated with nelfinavir and saquinavir HGC. Women and patients with hepatitis experienced a significantly greater number of adverse events compared with other categories. Gastrointestinal events were more frequently observed in patients treated with either ritonavir alone or in combination with saquinavir HGC, as well as in patients receiving nelfinavir, although in this group serious events were rare. Here again, neurologic, metabolic, and hepatic toxicity occurred more frequently in ritonavir and ritonavir-saquinavir HGC treated patients. Allergic reactions were more often observed in patients receiving nelfinavir. Indinavir-treated patients presented the highest incidence of renal toxicity. Conclusion: Ritonavir is the drug associated with the largest number of reactions, which appear during the first few months of treatment. Saquinavir HGC and nelfinavir are the best tolerated drugs in a clinical setting.",
keywords = "Adverse reactions, Antiretroviral therapy, Protease inhibitors, Surveillance",
author = "Paolo Bonfanti and Laura Valsecchi and Fabio Parazzini and Silvia Carradori and Luigi Pusterla and Paolo Fortuna and Lia Timillero and Federica Alessi and Giancarlo Ghiselli and Andrea Gabbuti and {Di Cintio}, Elisabetta and Canio Martinelli and Ivano Faggion and Simona Landonio and Tiziana Quirino",
year = "2000",
month = "3",
day = "1",
language = "English",
volume = "23",
pages = "236--245",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Incidence of adverse reactions in HIV patients treated with protease inhibitors

T2 - A cohort study

AU - Bonfanti, Paolo

AU - Valsecchi, Laura

AU - Parazzini, Fabio

AU - Carradori, Silvia

AU - Pusterla, Luigi

AU - Fortuna, Paolo

AU - Timillero, Lia

AU - Alessi, Federica

AU - Ghiselli, Giancarlo

AU - Gabbuti, Andrea

AU - Di Cintio, Elisabetta

AU - Martinelli, Canio

AU - Faggion, Ivano

AU - Landonio, Simona

AU - Quirino, Tiziana

PY - 2000/3/1

Y1 - 2000/3/1

N2 - Objective: To assess the probability that protease inhibitor (PI) therapy might be discontinued because of adverse events (AE) and to evaluate the incidence rate of adverse reactions during PI treatment. Design: A prospective cohort, multicenter study on HIV-positive patients starting treatment with at least one PI. Setting: Ten departments of infectious diseases in Northern Italy. Patients: A total of 1207 patients who started PI therapy in September 1997 and were consecutively observed up to April 1999. Main Outcome Measures: Adverse reactions following initiation of PI therapy, and time to therapy discontinuation due to AE. Results: During the study period, 35.9% patients presented adverse reactions of any grade, whereas 9.7% presented at least one serious AE. After 12 months of treatment, the percentage of patients who had interrupted treatment was 36% of ritonavir- treated patients, 14.2% of those treated with indinavir, 13.6% of ritonavir- saquinavir hard gel capsules (HGC)-treated patients, and 8.5% and 2.1%, respectively, for those treated with nelfinavir and saquinavir HGC. Women and patients with hepatitis experienced a significantly greater number of adverse events compared with other categories. Gastrointestinal events were more frequently observed in patients treated with either ritonavir alone or in combination with saquinavir HGC, as well as in patients receiving nelfinavir, although in this group serious events were rare. Here again, neurologic, metabolic, and hepatic toxicity occurred more frequently in ritonavir and ritonavir-saquinavir HGC treated patients. Allergic reactions were more often observed in patients receiving nelfinavir. Indinavir-treated patients presented the highest incidence of renal toxicity. Conclusion: Ritonavir is the drug associated with the largest number of reactions, which appear during the first few months of treatment. Saquinavir HGC and nelfinavir are the best tolerated drugs in a clinical setting.

AB - Objective: To assess the probability that protease inhibitor (PI) therapy might be discontinued because of adverse events (AE) and to evaluate the incidence rate of adverse reactions during PI treatment. Design: A prospective cohort, multicenter study on HIV-positive patients starting treatment with at least one PI. Setting: Ten departments of infectious diseases in Northern Italy. Patients: A total of 1207 patients who started PI therapy in September 1997 and were consecutively observed up to April 1999. Main Outcome Measures: Adverse reactions following initiation of PI therapy, and time to therapy discontinuation due to AE. Results: During the study period, 35.9% patients presented adverse reactions of any grade, whereas 9.7% presented at least one serious AE. After 12 months of treatment, the percentage of patients who had interrupted treatment was 36% of ritonavir- treated patients, 14.2% of those treated with indinavir, 13.6% of ritonavir- saquinavir hard gel capsules (HGC)-treated patients, and 8.5% and 2.1%, respectively, for those treated with nelfinavir and saquinavir HGC. Women and patients with hepatitis experienced a significantly greater number of adverse events compared with other categories. Gastrointestinal events were more frequently observed in patients treated with either ritonavir alone or in combination with saquinavir HGC, as well as in patients receiving nelfinavir, although in this group serious events were rare. Here again, neurologic, metabolic, and hepatic toxicity occurred more frequently in ritonavir and ritonavir-saquinavir HGC treated patients. Allergic reactions were more often observed in patients receiving nelfinavir. Indinavir-treated patients presented the highest incidence of renal toxicity. Conclusion: Ritonavir is the drug associated with the largest number of reactions, which appear during the first few months of treatment. Saquinavir HGC and nelfinavir are the best tolerated drugs in a clinical setting.

KW - Adverse reactions

KW - Antiretroviral therapy

KW - Protease inhibitors

KW - Surveillance

UR - http://www.scopus.com/inward/record.url?scp=12944265462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12944265462&partnerID=8YFLogxK

M3 - Article

C2 - 10839659

AN - SCOPUS:12944265462

VL - 23

SP - 236

EP - 245

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 3

ER -